

## Pooling all RCTs

Study or Subgroup	ERT		Control		Odds Ratio					Odds	s Ratio		
	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year			M-H, Rand	lom, 95% CI		
PROACTII	63	121	28	59	8.6%	1.20 [0.64, 2.24]	1999			_	<del>  •   •   •   •   •   •   •   •   •   •</del>		
Keris et al	8	12	7	33	3.1%	7.43 [1.72, 32.05]	2001				_		
Macleod et al	4	8	3	8	1.8%	1.67 [0.23, 12.22]	2005		_		<del>                                     </del>		$\rightarrow$
MELT	34	57	32	57	7.3%	1.15 [0.55, 2.43]	2007			-	-		
SYNTHESIS pilot	16	25	15	29	4.7%	1.66 [0.56, 4.96]	2009			-	-		
MR RESCUE	22	64	23	54	7.3%	0.71 [0.33, 1.49]	2013			-	-		
IMS III	248	415	121	214	12.0%	1.14 [0.82, 1.59]	2013			_	-		
SYNTHESIS EXPANSION	113	181	112	181	10.9%	1.02 [0.67, 1.57]	2013			- 1	-		
MR CLEAN	119	233	95	267	11.7%	1.89 [1.32, 2.71]	2014						
REVASCAT	64	103	49	103	9.4%	1.81 [1.04, 3.15]	2015				-		
SWIFT PRIME	71	98	49	93	8.8%	2.36 [1.29, 4.31]	2015					_	
EXTEND-IA	31	35	18	35	4.0%	7.32 [2.13, 25.15]	2015				1,000		
ESCAPE	114	164	65	147	10.4%	2.88 [1.81, 4.58]	2015				-	_	
Total (95% CI)		1516		1280	100.0%	1.66 [1.25, 2.22]					•		
Total events	907		617										
Heterogeneity: Tau2 = 0.15;	Chi2 = 33	.03, df	= 12 (P =	0.0010	$); I^2 = 649$	%		-	-1-	0.5	<del>                                     </del>	<u> </u>	- 40
Test for overall effect: $Z = 3$ .	45 (P = 0.	0006)			50.			0.1	0.2 Favo	0.5 ours Control	Favours ER	Г	10

## Pooling stent-retriever RCTs

**ERT** Control **Odds Ratio Odds Ratio** Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl Year M-H, Random, 95% CI MR CLEAN 119 233 95 267 32.4% 1.89 [1.32, 2.71] 2014 REVASCAT 64 103 49 103 19.8% 1.81 [1.04, 3.15] 2015 SWIFT PRIME 71 98 49 93 17.7% 2.36 [1.29, 4.31] 2015 EXTEND-IA 31 35 18 35 5.4% 7.32 [2.13, 25.15] 2015 **ESCAPE** 114 164 65 147 24.7% 2.88 [1.81, 4.58] 2015 Total (95% CI) 633 645 100.0% 2.33 [1.72, 3.15] 399 Total events 276 Heterogeneity: Tau2 = 0.04; Chi2 = 6.11, df = 4 (P = 0.19); I2 = 35% 0.5 10 Test for overall effect: Z = 5.48 (P < 0.00001) Favours Control Favours ERT

## Pooling RCTs with IV-TPA rate > 75% in control arms

Study or Subgroup	ERT		Contr	ol		Odds Ratio				Odd	s Ratio			
	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year			M-H, Ran	dom, 95%	CI		
SYNTHESIS pilot	16	25	15	29	6.4%	1.66 [0.56, 4.96]	2009				-	V-10-00	-	
SYNTHESIS EXPANSION	113	181	112	181	15.2%	1.02 [0.67, 1.57]	2013			-	-			
IMS III	248	415	121	214	16.8%	1.14 [0.82, 1.59]	2013				-			
MR CLEAN	119	233	95	267	16.4%	1.89 [1.32, 2.71]	2014				-	_		
SWIFT PRIME	71	98	49	93	12.2%	2.36 [1.29, 4.31]	2015				-	•		
REVASCAT	64	103	49	103	13.0%	1.81 [1.04, 3.15]	2015							
EXTEND-IA	31	35	18	35	5.4%	7.32 [2.13, 25.15]	2015							$\rightarrow$
ESCAPE	114	164	65	147	14.5%	2.88 [1.81, 4.58]	2015				-	•	-	
Total (95% CI)		1254		1069	100.0%	1.83 [1.31, 2.56]					•	-		
Total events	776		524											
Heterogeneity: Tau2 = 0.14;	Chi2 = 22	.62, df	= 7 (P = 0	1.002);	$l^2 = 69\%$			-	1	- 1-	+ 1		<u>+</u>	7
Test for overall effect: Z = 3.	55 (P = 0.	0004)	0046 1					0.1	0.2 Favo	0.5 ours Contro	1 Z	s ERT	5	10

Supplementary Figure 1. Pooled estimates for achieving modified Rankin Scale (mRS) 0-3 outcomes with Endovascular recanalization therapy vs. control.

B

0

A